Brain Imaging of Psychotherapy for Posttraumatic Stress Disorder (PTSD)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators are seeking people who have been exposed to a traumatic event in the past and have symptoms of posttraumatic stress disorder (PTSD) currently. A person with PTSD may feel significant distress when reminded of a traumatic event or feel depressed, anxious or jumpy.
As a part of this study, participants will receive brain MRIs and office assessments before and after psychotherapy. The investigators provide the gold-standard psychotherapy for PTSD, "Prolonged Exposure", free of charge; additionally participants are compensated for their time during assessment procedures. This study is exploring the brain circuitry involved in improvement in response to psychotherapy.
| Condition | Intervention |
|---|---|
|
Posttraumatic Stress Disorder (PTSD) |
Behavioral: Prolonged exposure Behavioral: Prolonged Exposure |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | The Neurobiology of Psychotherapy: Emotional Reactivity and Regulation in PTSD |
- Clinician Administered PTSD scale (CAPS) [ Time Frame: Before and after Prolonged Exposure Treatment, which is expected to take approximately six weeks. ] [ Designated as safety issue: No ]The CAPS is a 30-item structured interview that corresponds to the DSM-IV criteria for PTSD. In addition to assessing the 17 PTSD symptoms, questions target the impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and frequency and intensity of five associated symptoms (guilt over acts, survivor guilt, gaps in awareness, depersonalization, and derealization). For each item, standardized questions and probes are provided.
- Mood and Anxiety Symptom Questionnaire (MASQ) [ Time Frame: Before and after Prolonged Exposure Treatment, which is expected to take approximately six weeks. ] [ Designated as safety issue: No ]Treatment success based on Improvement on subscales of the MASQ, including decreased anxious arousal and decreased anhedonic depression, from pre- to post-treatment assessment
- fMRI-assessed resting connectivity [ Time Frame: Before and after Prolonged Exposure Treatment, which is expected to take approximately six weeks. ] [ Designated as safety issue: No ]From pre- to post-treatment, improve will be based on enhanced functional connectivity
- Implicit emotion regulation [ Time Frame: Assessed 4 times: Before beginning Prolonged Exposure, after the third week of therapy, after the last therapy session (on average 6 weeks after beginning therapy), and 1 month after the end of therapy. ] [ Designated as safety issue: No ]Implicit emotion regulation assessed through emotion conflict task performed during functional imaging. Performance based on reaction time and recruitment of emotion regulation regions during the task.
| Estimated Enrollment: | 64 |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | September 2015 |
| Estimated Primary Completion Date: | September 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Immediate Prolonged Exposure Treatment
Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
|
Behavioral: Prolonged exposure
PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
|
|
No Intervention: Wait list, immediately followed by Prolonged Exposure
Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
|
Behavioral: Prolonged Exposure
PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
|
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age between 18 and 60 years;
- fMRI scanning eligibility, including no evidence of any form of metal embedded in the body (e.g., metal wires, nuts, bolts, screws, plates, sutures), as these produce artifacts when brain imaging;
- not currently involved in an exposure-based psychotherapy, in order to be able to measure and interpret the effects of PE on PTSD;
- must comprehend English well and show non-impaired intellectual abilities to ensure adequate comprehension of the fMRI task instructions and PE treatment;
- no history of neurological or cardiovascular disorders, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, stroke, seizures or epilepsy, diabetes, hypo- or hyperthyroidism, head trauma with loss of consciousness greater than thirty minutes;
- no regular use of benzodiazepine, opiate, thyroid, anticonvulsant or antipsychotic medications. Patients on stable doses of antidepressant medications will be allowed. Patients for whom antidepressant dosing is being actively titrated will be required to be on a stable dose for 1 month prior to inclusion in the study.
Exclusion Criteria:
- Any contraindication to being scanned in the 3T or 1.5T scanners at the Lucas Center or CNI such as having a pacemaker or implanted device that has not been cleared for scanning at the Lucas Center or CNI.
- Participants will be excluded from the study if there is any lifetime evidence of psychosis, mania, hypomania, or bipolar disorders. Other axis I comorbidities will not be a cause for exclusion.
In addition, subjects will be excluded if they have a significant CNS neurological condition such as stroke, seizure, tumor, hemorrhage, multiple sclerosis, etc.
Patients who have current substance dependence will be excluded from the study. A recent diagnosis of substance abuse is allowable, however, as long as subjects have been abstinent for greater than three months.
- Subjects will be excluded if they are currently in an exposure-based psychotherapy for PTSD.
Contacts and Locations| Contact: Kathy Peng, B.A. | 650-725-9510 | psychiatry@stanford.edu |
| Contact: Madeleine Goodkind, PhD | 650-493-5000 ext 60168 | mgoodkin@stanford.edu |
| United States, California | |
| VA Palo Alto Healthcare System | Recruiting |
| Palo Alto, California, United States, 94304 | |
| Contact: Kathy Peng, B.A. 650-725-9510 psychiatry@stanford.edu | |
| Contact: Madeleine Goodkind, Ph.D. 650-493-5000 ext 60168 mgoodkin@stanford.edu | |
| Principal Investigator: Amit Etkin, M.D., Ph.D. | |
| Stanford University, Department of Psychiatry | Recruiting |
| Stanford, California, United States, 94304 | |
| Contact: Kathy Peng, B.A. 650-725-9510 psychiatry@stanford.edu | |
| Contact: Madeleine Goodkind, Ph.D. 650-725-9510 mgoodkin@stanford.edu | |
| Principal Investigator: Amit Etkin, M.D., Ph.D. | |
| Principal Investigator: | Amit Etkin, M.D., Ph.D. | Stanford University |
| Study Director: | Madeleine S Goodkind, Ph.D. | Stanford University |
More Information
Additional Information:
No publications provided
| Responsible Party: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT01507948 History of Changes |
| Other Study ID Numbers: | SU-10252011-8566 |
| Study First Received: | December 14, 2011 |
| Last Updated: | January 13, 2012 |
| Health Authority: | United States: Institutional Review Board United States: Federal Government |
Keywords provided by Stanford University:
|
Posttraumatic Stress Disorder (PTSD) Psychotherapy non-medication treatment Prolonged Exposure Transcranial Magnetic Stimulation (TMS) |
Anxiety Disorders emotion emotion regulation functional MRI Affective Symptoms |
Additional relevant MeSH terms:
|
Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Anxiety Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 21, 2013